Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease

World Journal of Gastroenterology

Volumn 11, Issue 4, 2005, Pages 476-481

  Saitou, Yukiko ^a   Shiraki, Katsuya ^a   Yamanaka, Yutaka ^a   Yamaguchi, Yumi ^a   Kawakita, Tomoyuki ^a   Yamamoto, Norihiko ^a   Sugimoto, Kazushi ^a   Murata, Kazumoto ^a   Takeshi, Nakano ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

HCV; Interferon; Liver fibrosis; YKL 40

Indexed keywords

COLLAGEN TYPE 4; GLYCOPROTEIN GP 39; HYALURONIC ACID; INTERFERON; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE;

ADULT; AGED; AMINO TERMINAL SEQUENCE; AREA UNDER THE CURVE; ARTICLE; CHEMICAL PARAMETERS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROGENESIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LIVER BIOPSY; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; NON INVASIVE MEASUREMENT; NONHUMAN; PREDICTION; RADIOIMMUNOASSAY; RECEIVER OPERATING CHARACTERISTIC;

EID: 13244255642     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i4.476     Document Type: Article

References (43)

1. Forns X, Ampurdanes S, Sanchez-Tapias JM, Guilera M, Sans M, Sanchez-Fueyo A. Quinto L, Joya P, Bruguera M, Rodes J. Long-term follow-up of chronic hepatitis C in patients diagnosed at a tertiary-care center. J Hepatol 2001; 35: 265-271
2. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, Hashimoto E, Lefkowitch JH, Ludwig J, Okuda K. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996; 23: 1334-1340
3. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the group of epidemiology of the french association for the study of the liver (AFEF). Hepatology 2000; 32: 477-481
4. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526
5. Pares A, Deulofeu R, Gimenez A, Caballeria L, Bruguera M, Caballeria J, Ballesta AM, Rodes J. Serum hyaluronate reflects hepatic fibrogenesis; in alcoholic liver disease and is useful as a marker of fibrosis. Hepatology 1996; 24: 1399-1403
6. Nojgaard C, Johansen JS, Christensen E, Skovgaard LT, Price PA, Becker U. EMALD group. Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease. J Hepatol 2003; 2: 179-186
7. Nojgaard C, Johansen JS, Krarup HB, Holten-Andersen M, Moller A, Bendtsen F. Effect of antiviral therapy on markers of fibrogenesis in patients with chronic hepatitis C. Scand J Gastroenterol 2003; 38: 659-665
8. Murawaki Y, Ikuta Y, Koda M, Yamada S, Kawasaki H. Comparison of serum 7S fragment of type IV collagen and serum central triple-helix of type IV collagen for assessment of liver fibrosis in patients with chronic viral liver disease. J Hepatol 1996; 24: 148-154
9. Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, Bruguera M, Sanchez-Tapias JM, Rodes J. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 986-992
10. Guechot J, Poupon RE, Giral P, Balkau B, Giboudeau J, Poupon R. Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C. J Hepatol 1994; 20: 388-393
11. Patel K, Lajoie A, Heaton S, Pianko S, Behling CA, Bylund D, Pockros PJ, Blatt LM, Conrad A, McHutchison JG. Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C. J Gastroenterol Hepatol 2003; 18: 253-257
12. McHutchison JG, Blatt LM, de Medina M, Craig JR, Conrad A, Schiff ER, Tong MJ. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus interferon study group. J Gastroenterol Hepatol 2000; 15: 945-951
13. Hakala BE, White C, Recklies AD. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem 1993; 268: 25803-25810
14. Hu B, Trinh K, Figueira WF, Price PA. Isolation and sequence of a novel human chondrocyte protein related to mammalian members of the chitinase protein family. J Biol Chem 1996; 271: 19415-19420
15. Johansen JS, Jensen HS, Price PA. A new biochemical marker for joint injury. Analysis of YKL-40 in serum and synovial fluid. Br J Rheumatol 1993; 32: 949-955
16. Peltomaa R, Paimela L, Harvey S, Helve T, Leirisalo-Repo M. Increased level of YKL-40 in sera from patients with early rheumatoid arthritis: a new marker for disease activity. Rheumatol Int 2001; 20: 192-196
17. Johansen JS, Hvolris J, Hansen M, Backer V, Lorenzen I, Price PA. Serum YKL-40 levels in healthy children and adults. Comparison with serum and synovial fluid levels of YKL-40 in patients with osteoarthritis or trauma of the knee joint. Br J Rheumatol 1996; 35: 553-559
18. Tran A, Benzaken S, Saint-Paul MC, Guzman-Granier E, Hastier P, Pradier C, Barjoan EM, Demuth N, Longo F, Rampal P. Chondrex (YKL-40), a potential new serum fibrosis marker in patients with alcoholic liver disease. Eur J Gastroenterol Hepatol 2000; 12: 989-993
19. Johansen JS, Christoffersen P, Moller S, Price PA, Henriksen JH, Garbarsch C, Bendtsen F. Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol 2000; 32: 911-920
20. Sztrolovics R, Recklies AD, Roughley PJ, Mort JS. Hyaluronate degradation as an alternative mechanism for proteoglycan release from cartilage during interleukin-1beta-stimulated catabolism. Biochem J 2002; 362: 473-479
21. Malinda KM, Ponce L, Kleinman HK, Shackelton LM, Millis AJ. Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res 1999; 250: 168-173
22. Afdhal NH. Diagnosing fibrosis in hepatitis C: is the pendulum swinging from biopsy to blood tests ? Hepatology 2003; 37: 972-974
23. Fontana RJ, Lok AS. Noninvasive monitoring of patients with chronic hepatitis C. Hepatology 2002; 36(5 Suppl 1): S57-S64
24. Murawaki Y, Ikuta Y, Koda M, Kawasaki H. Serum type III procollagen peptide, type IV collagen 7S domain, central triple-helix of type IV collagen and tissue inhibitor of metalloproteinases in patients with chronic viral liver disease: relationship to liver histology. Hepatology 1994; 20: 780-787
25. Smedsrod B. Aminoterminal propeptide of Type III procollagen is cleared from the circulation by receptor-mediated endocytosis in liver endothelial cells. Coll Relat Res 1988; 8: 375-388
26. Takai K, Hattori S, Irie S. Type V collagen distribution in liver is reconstructed in coculture system of hepatocytes and stellate cells; the possible functions of Type V collagen in liver under normal and pathological conditions. Cell Struct Funct 2001; 26: 289-302
27. Plebani M, Giacomini A, Floreani A, Chiaramonte M, Soffiati G, Naccarato R, Burlina A. Biochemical markers of hepatic fibrosis in primary biliary cirrhosis. Ric Clin Lab 1990; 20: 269-274
28. Ramadori G, Zohrens G, Manns M, Rieder H, Dienes HP, Hess G, Meyer KH, Buschenfelde Z, Buschenfelde Z. Serum hyaluronate and type III procollagen aminoterminal propeptide concentration in chronic liver disease. Relationship to cirrhosis and disease activity. Eur J Clin Invest 1991; 21: 323-330
29. Murawaki Y, Ikuta Y, Idobe Y, Koda M, Kawasaki H. Molecular weight of hyaluronate in the serum of patients with chronic liver disease. Res Commun Mol Pathol Pharmacol 1998; 99: 207-216
30. Gressner AM, Bachem MG. Cellular sources of noncollagenous matrix proteins: role of fat-storing cells in fibrogenesis. Semin Liver Dis 1990; 10: 30-46
31. McHutchison JG, Blatt LM, de Medina M, Craig JR, Conrad A, Schiff ER, Tong MJ. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus interferon study group. J Gastroenterol Hepatol 2000; 15: 945-951
32. Johansen JS, Moller S, Price PA, Bendtsen F, Junge J, Garbarsch C, Henriksen JH. Plasma YKL-40: a new potential marker of fibrosis in patients with alcoholic cirrhosis ? Scand J Gastroenterol 1997; 32: 582-590
33. Johansen JS, Cintin C, Jorgensen M, Kamby C, Price PA. Serum YKL-40: a new potential marker of prognosis and location of metastases of patients with recurrent breast cancer. Eur J Cancer 1995; 31: 1437-1442
34. Cintin C, Johansen JS, Christensen IJ, Sorensen S, Nielsen HJ. Serum YKL-40 and colorectal cancer. Br J Cancer 1999; 79: 1494-1499
35. Renkema GH, Boot RG, Au FL, Donker-Koopman WE, Strijland A, Muijsers AO, Hrebicek M, Aerts JM. Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. Eur J Biochem 1998; 251: 504-509
36. Volck B, Price PA, Johansen JS, Sorensen O, Benfield TL, Nielsen HJ, Calafat J, Borregaard N. YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians 1998; 110: 351-360
37. Johansen JS, Christoffersen P, Møller S, Price PA, Henriksen JH, Garbarsch C, Bendtsen F. Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol 2000; 32: 911-920
38. Shiratori Y, Omata M. Predictors of the efficacy of interferon therapy for patients with chronic hepatitis C before and during therapy: how does this modify the treatment course ? J Gastroenterol Hepatol 2000; 15(Suppl): E141-E151
39. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-832
40. Mathurin P, Moussalli J, Cadranel JF, Thibault V, Charlotte F, Dumouchel P, Cazier A, Huraux JM, Devergie B, Vidaud M, Opolon P, Poynard T. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998; 27: 868-872
41. Omata M, Shiratori Y. Long-term effects of interferon therapy on histology and development of hepatocellular carcinoma in hepatitis C. J Gastroenterol Hepatol 2000; 15(Suppl): E134-E140
42. Reichard O, Glaumann H, Fryden A, Norkrans G, Schvarcz R, Sonnerborg A, Yun ZB, Weiland O. Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. Hepatology 1995; 21: 918-922
43. Manesis EK, Papaioannou C, Gioustozi A, Kafiri G, Koskinas J, Hadziyannis SJ. Biochemical and virological outcome of patients with chronic hepatitis C treated with interferon alfa-2b for 6 or 12 mo: a 4-year follow-up of 211 patients. Hepatology 1997; 26: 734-739